# Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

> **NCT01522872** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Threshold Pharmaceuticals** · enrollment: 98 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** TH-302
- **DRUG:** TH-302 and Dexamethasone
- **DRUG:** TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib
- **DRUG:** TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide

## Key facts

- **NCT ID:** NCT01522872
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-02
- **Primary completion:** 2016-09
- **Final completion:** 2017-09
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2016-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01522872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01522872, "Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01522872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*